Alkermes Plc (ALKS)
47.35
+0.15
(+0.32%)
USD |
NASDAQ |
Sep 02, 14:16
Alkermes Research and Development Expense (TTM) : 384.84M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 384.84M |
| March 31, 2026 | 349.59M |
| December 31, 2025 | 318.36M |
| September 30, 2025 | 283.30M |
| June 30, 2025 | 261.45M |
| March 31, 2025 | 243.83M |
| December 31, 2024 | 239.63M |
| September 30, 2024 | 256.88M |
| June 30, 2024 | 293.13M |
| March 31, 2024 | 332.97M |
| December 31, 2023 | 328.23M |
| September 30, 2023 | 327.31M |
| June 30, 2023 | 329.90M |
| March 31, 2023 | 321.78M |
| December 31, 2022 | 353.47M |
| September 30, 2022 | 375.83M |
| June 30, 2022 | 394.01M |
| March 31, 2022 | 398.61M |
| December 31, 2021 | 394.33M |
| September 30, 2021 | 407.46M |
| June 30, 2021 | 382.83M |
| March 31, 2021 | 378.78M |
| December 31, 2020 | 379.49M |
| September 30, 2020 | 378.74M |
| June 30, 2020 | 391.93M |
| Date | Value |
|---|---|
| March 31, 2020 | 402.54M |
| December 31, 2019 | 412.23M |
| September 30, 2019 | 410.35M |
| June 30, 2019 | 404.54M |
| March 31, 2019 | 407.33M |
| December 31, 2018 | 413.11M |
| September 30, 2018 | 408.92M |
| June 30, 2018 | 412.37M |
| March 31, 2018 | 405.00M |
| December 31, 2017 | 402.39M |
| September 30, 2017 | 388.03M |
| June 30, 2017 | 383.66M |
| March 31, 2017 | 382.31M |
| December 31, 2016 | 379.25M |
| September 30, 2016 | 383.91M |
| June 30, 2016 | 377.62M |
| March 31, 2016 | 368.90M |
| December 31, 2015 | 338.20M |
| September 30, 2015 | 318.65M |
| June 30, 2015 | 303.76M |
| March 31, 2015 | 282.48M |
| December 31, 2014 | 265.94M |
| September 30, 2014 | 242.23M |
| June 30, 2014 | 212.01M |
| March 31, 2014 | 178.06M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Amarin Corp. Plc | 16.15M |
| Jazz Pharmaceuticals Plc | 815.61M |
| Prothena Corp. Plc | 64.95M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Biogen, Inc. | 1.736B |